kabutan

KISSEI PHARMA, Ordinary Profit Forecast for the Fiscal Year Loss to Narrow

Tue Nov 4, 2025 3:30 pm JST Earnings

4547 KISSEI PHARMACEUTICAL CO.,LTD. 【J-GAAP】

Earnings Report

KISSEI PHARMACEUTICAL CO.,LTD. <4547> [TSE Prime] announced its financial results after the market closed on November 4th (15:30). The consolidated ordinary profit/loss for the cumulative second quarter of the fiscal year ending March 2026 (April to September) turned into a loss of 5.62 billion yen (compared to a profit of 2.23 billion yen in the same period last year).

However, the full-year forecast for consolidated ordinary profit/loss has been revised upward from an expected loss of 2.60 billion yen to a loss of 1.10 billion yen (compared to a profit of 6.97 billion yen in the previous period), indicating a reduction in the loss margin.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated ordinary profit for the October to March period (second half) is expected to decrease 4.5% from the same period last year to 4.52 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated ordinary loss expanded to a loss of 8.53 billion yen (compared to a loss of 0.63 billion yen in the same period last year). The operating profit/loss margin drastically worsened from -1.8% in the same period last year to -37.8%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 36,978 2,015 3,465 5,678 123.7 56.4 Nov 6, 2023 J-GAAP
Apr - Sep, 2024 42,466 1,781 2,237 5,249 118.8 32.1 Nov 5, 2024 J-GAAP
Apr - Sep, 2025 45,831 -6,837 -5,622 7,784 186.8 ー Nov 4, 2025 J-GAAP
YoY +7.9% － － +48.3% +57.3%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance 44,300 -7,700 -6,900 6,200 149.6 60 Jul 29, 2025 J-GAAP
Apr - Sep, 2025 Results 45,831 -6,837 -5,622 7,784 186.8 60 Nov 4, 2025 J-GAAP
Revision Rate +3.5% +11.2% +18.5% +25.5% +24.9%

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 91,500 -4,000 -2,600 12,300 296.7 120 Jul 29, 2025 J-GAAP
Mar, 2026 New 95,500 -2,600 -1,100 12,700 306.4 120 Nov 4, 2025 J-GAAP
Revision Rate +4.4% +35.0% +57.7% +3.3% +3.3%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 45,864 3,992 4,737 6,712 153.9 55 May 7, 2025 J-GAAP
Oct - Mar, 2025 Guidance 49,669 4,237 4,522 4,916 118.6 60 Nov 4, 2025 J-GAAP
YoY +8.3% +6.1% -4.5% -26.8% -22.9%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 75,579 4,017 6,142 11,160 246.6 82 May 7, 2024 J-GAAP
Mar, 2025 88,330 5,773 6,974 11,961 274.2 100 May 7, 2025 J-GAAP
Mar, 2026 Guidance 95,500 -2,600 -1,100 12,700 306.4 120 Nov 4, 2025 J-GAAP
YoY +8.1% － － +6.2% +11.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 21,302 -377 -639 1,143 25.9 -1.8 Nov 5, 2024 J-GAAP
Oct - Dec, 2024 23,203 2,457 3,061 3,591 81.8 10.6 Feb 3, 2025 J-GAAP
Jan - Mar, 2025 22,661 1,535 1,676 3,121 71.6 6.8 May 7, 2025 J-GAAP
Apr - Jun, 2025 22,191 2,108 2,915 4,519 107.9 9.5 Jul 29, 2025 J-GAAP
Jul - Sep, 2025 23,640 -8,945 -8,537 3,265 78.4 -37.8 Nov 4, 2025 J-GAAP
YoY +11.0% -2,272.7% -1,236.0% +185.7% +203.0%

Related Articles